Blood Lead Levels and Serum Insulin-Like Growth Factor 1 Concentrations in Peripubertal Boys

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

**Citation**

**Published Version**
doi:10.1289/ehp.1206105

**Citable link**
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717530

**Terms of Use**
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Blood Lead Levels and Serum Insulin-Like Growth Factor 1 Concentrations in Peripubertal Boys

Abby F. Fleisch,1 Jane S. Burns,2 Paige L. Williams,3 Mary M. Lee,4,5 Oleg Sergeyev,6,7 Susan A. Korrick,2,8 and Russ Hauser2

1Department of Endocrinology, Children’s Hospital Boston, Boston, Massachusetts, USA; 2Department of Environmental Health, and 3Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA; 4Department of Pediatrics, and 5Department of Cell Biology, Pediatric Endocrine Division, University of Massachusetts Medical School, Worcester, Massachusetts, USA; 6Department of Physical Education and Health, Samara State Medical University, Samara, Russian Federation; 7Chapaevsk Medical Association, Chapaevsk, Russian Federation; 8Channing Division of Network Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA

BACKGROUND: Childhood lead exposure has been associated with growth delay. However, the association between blood lead levels (BLLs) and insulin-like growth factor 1 (IGF-1) has not been characterized in a large cohort with low-level lead exposure.

METHODS: We recruited 394 boys 8–9 years of age from an industrial Russian town in 2003–2005 and followed them annually thereafter. We used linear regression models to estimate the association of baseline BLLs with serum IGF-1 concentration at two follow-up visits (ages 10–11 and 12–13 years), adjusting for demographic and socioeconomic covariates.

RESULTS: At study entry, median BLL was 3 μg/dL (range, < 0.5–31 μg/dL); most boys (86%) were prepubertal, and mean ± SD height and BMI z-scores were 0.14 ± 1.0 and 0.2 ± 1.3, respectively. After adjustment for covariates, the mean follow-up IGF-1 concentration was 29.2 ng/mL lower (95% CI: –43.8, –14.5) for boys with high versus low BLL (≥ 5 μg/dL or < 5 μg/dL); this difference persisted after further adjustment for pubertal status. The association of BLL with IGF-1 was stronger for mid-pubertal than prepubertal boys (p = 0.04). Relative to boys with BLLs < 2 μg/dL, adjusted mean IGF-1 concentrations decreased by 12.8 ng/mL (95% CI: –29.9, 4.4) for boys with BLLs of 3–4 μg/dL; 34.5 ng/mL (95% CI: –53.1, –16.0) for BLLs 5–9 μg/dL; and 60.4 ng/mL (95% CI: –90.9, –29.9) for BLLs ≥ 10 μg/dL.

CONCLUSIONS: In peripubertal boys with low-level lead exposure, higher BLLs were associated with lower serum IGF-1. Inhibition of the hypothalamic–pituitary–growth axis may be one possible pathway by which lead exposure leads to growth delay.

KEY WORDS: cohort studies, growth, insulin-like growth factor 1, lead, puberty.


The Centers for Disease Control and Prevention (CDC) recently revised the reference value for childhood lead exposure downward from 10 to 5 μg/dL (Betsis 2012). This has occurred in response to evidence showing consistent associations between blood lead levels (BLLs) < 10 μg/dL and neurocognitive (Bellinger et al. 1992; Lanphear et al. 2005), cardiovascular (Gump et al. 2005; Menke et al. 2006), and immunologic (Karmaus et al. 2005) outcomes, as well as pubertal (Kafourou et al. 1997; Naicker et al. 2010; Selevan et al. 2003; Shukla et al. 1991; Williams et al. 2010) and growth delay (Ballew et al. 1999; Little et al. 2009; Schwartz et al. 1986).

In cross-sectional studies conducted in prepubertal children, mean decreases of 1–1.5 cm in height have been estimated for each 10-μg/dL increase in BLL (Ballew et al. 1999; Little et al. 2009; Schwartz et al. 1986). BLL has also been negatively associated with height in two pubertal cohorts (Burns et al. 2012; Selevan et al. 2003). In our prospective cohort of Russian boys followed annually from 8 to 13 years of age, boys with BLL ≥ 5 μg/dL had significantly lower mean height z-score (–0.44) than boys with BLL < 5 μg/dL (Burns et al. 2012).

A mechanistic explanation for the association between lead exposure and growth delay in childhood has not been firmly established. Studies to this end have been conducted almost exclusively in animal models with high lead exposures, and results have suggested multiple possible mechanisms, perhaps operating simultaneously, including lead-induced reduction in food consumption (Hammond et al. 1989, 1990) and direct growth plate effects (Hass et al. 1967; Hicks et al. 1996). Several rodent studies have also implicated lead-mediated suppression of growth hormone (GH) release from the pituitary (Camoratto et al. 1993; Lau et al. 1991; Ronis et al. 1998a) and consistent with this finding, high lead exposure has been associated with decreased serum insulin-like growth factor 1 (IGF-1) concentration in rodents (Ronis et al. 1998a) and prepubertal children (Husman et al. 1992).

The physiologic mechanisms that mediate health outcomes such as growth delay following low lead exposure may be different from those operating at higher exposures. Mechanistic differences in low- versus high-dose effects have been demonstrated for several environmental chemicals, including bisphenol A, atrazine, dioxin, and perchlorate (Vandenbergh et al. 2012). Because exposures to lead and other heavy metals are increasingly regulated, a better understanding of the physiologic effects of low-level exposures is needed. With regard to growth delay, the relationship between low-level lead exposure and serum IGF-1 concentration has not been examined.

The present analysis was conducted to evaluate the association between childhood BLL and longitudinally measured serum IGF-1 concentrations and to assess whether there is a dose–response relationship between BLL and IGF-1 in a large cohort of peripubertal boys with low-level lead exposure.

Methods

Study population. From 2003–2005, we recruited 8–9-year-old boys in Chapaevsk, Russia, to participate in the Russian Children’s Study, as previously described (Burns et al. 2012). Enrollment exclusion criteria included being institutionalized or having severe cerebral palsy. A total of 499 boys were thus identified, and they have been followed annually since recruitment. For the present analysis, 10 boys with severe chronic illnesses that could affect growth were excluded. Of the remaining 489, two pubertal boys were also excluded.

Address correspondence to R. Hauser, Department of Environmental Health, Harvard School of Public Health (Bldg 1, 14th floor), 605 Huntington Ave., Boston, MA 02115 USA. Telephone: (617) 432-3326. E-mail: rhauser@hsph.harvard.edu

We thank the former chief of Chapaevsk Central Hospital, V. Zeilert, and the staff of the Chapaevsk Medical Association. We also thank our colleagues B. Revich from the Institute for Forecasting, RAS, Moscow; A. Safronova and M. Starovoytov from the Russian Institute of Nutrition, Moscow; and staff of EFIS, Moscow laboratory. We thank L.E. Cohen for helpful discussions.

We have received support from the following grants: R28943701 from the U.S. Environmental Protection Agency; ES014370, ES000002, and ES017117 from the National Institute of Environmental Health Sciences; and T32 ES000063 from the Agency of Healthcare Research and Quality. M.M.L. is a member of the National Institute of Diabetes and Digestive and Kidney Disease–funded UMass Diabetes Research Center (DRC P30DK032520). The authors declare they have no actual or potential competing financial interests.

Received 5 October 2012; accepted 24 April 2013.
from the analysis because of implausibly low IGF-1 concentrations (< 50 ng/mL) despite normal height and body mass index (BMI) z-scores. Of the remaining 487 boys, 394 met inclusion criteria for this analysis, specifically, by availability of a baseline BLL (at 8–9 years) and follow-up serum IGF-1 concentration at both the 2-year (at 10–11 years) and the 4-year (at 12–13 years) follow-up visits. None of the participants had IGF-1 measured at baseline or BLL measured at follow-up. The Russian Children’s Study was approved by the human studies institutional review boards (IRBs) of the Chapaevik Medical Association, Harvard School of Public Health, Brigham and Women’s Hospital, and University of Massachusetts Medical School. The parent or guardian of each Russian Children’s Study participant signed an informed consent form, and each boy signed an assent form. The present analysis was a secondary data analysis that was exempt from requirement for IRB review of already collected, deidentified data under federal and Children’s Hospital Boston policies.

### Study assessment protocol

At study entry, boys underwent a physical examination and blood collection. We used a validated Russian Institute of Nutrition semiquantitative food-frequency questionnaire to estimate dietary intakes during the previous year (Martinchik et al. 1998; Rockett et al. 1997). Mothers or guardians also completed nurse-administered health and lifestyle questionnaires that included information on birth, family and child medical histories, occupational and residential history, and measures of socioeconomic status (SES) such as household income and parental education. We obtained birth weight and gestational age from medical records.

### Physical examination

A single study nurse who did not have knowledge of the boys’ BLLs performed standardized anthropometric examinations, and a single investigator (O.S.) performed pubertal assessments at study entry and at annual follow-up visits. We measured height to the nearest 0.1 cm with a stadiometer. We measured weight to the nearest 100 g with a metric scale. We calculated age-adjusted percentiles for BMI (kilograms per meter squared) using the World Health Organization (WHO) standards (WHO 2011). For this analysis, pubertal status was based on testicular volume measured by Prader beads (orchiometer).

### Blood lead levels

Venous blood samples (3.0 mL) were collected in trace metal-free Vacutainer tubes (Becton-Dickinson, Franklin Lakes, NJ, USA), after cleansing the venipuncture site with alcohol. Whole-blood samples were diluted with a matrix modifier solution and analyzed using Zeeman background corrected, flameless graphite furnace, atomic absorption spectrometry (ESA Laboratories, Chelmsford, MA, USA). BLLs below the limit of detection (1 μg/dL) were imputed as 0.5 μg/dL for 9 (2.2%) of 394 boys.

### Serum IGF-1 concentrations

Serum IGF-1 concentrations were measured by a chemiluminescent immunometric assay using Siemens Immulite 2000 (Siemens AG, Munich, Germany). The assay is highly specific for IGF-1 with undetectable cross-reactivity with insulin, pro-insulin, luteinizing hormone (LH), thyroid-stimulating hormone, or insulin-like growth factor-2. The detection limit was 20 ng/mL; no IGF-1 values were below the limit of detection. The intra-assay coefficient of variation (CV) was < 3.9%, and the inter-assay CV was < 8.1% for the Immulite 2000 kit.

### Statistical analysis

We used repeated measures analysis to estimate the association between BLL measured at 8–9 years of age and serum IGF-1 concentration at both the 2-year (at 10–11 years) and 4-year (at 12–13 years) follow-up visits. The distribution of BLLs was right-skewed with outliers. We considered several different ways of evaluating BLLs, including dichotomized as high (≥ 5 μg/dL) versus low (< 5 μg/dL) based on the new CDC threshold, as a continuous measure (log-transformed), and categorized as 0–2, 3–4, 5–9, or ≥ 10 μg/dL.

We fit linear regression models using a generalized estimating equation (GEE) approach to account for the repeated measures and slight skewness of IGF-1 concentrations. We first fit GEE linear regression models to evaluate unadjusted associations of high versus low BLL (≥ 5 or < 5 μg/dL) with serum IGF-1 concentrations. Next, we created a full multivariable model that included dichotomized BLL, birth weight (continuous), gestational age at birth (continuous), breastfeeding duration (< 12, 12–24, or > 24 weeks), maximum parental education (secondary education or less, junior college/technical training, or university graduate), monthly household income (< US$175, $175–250, or > $250), nutritional intake (total caloric intake and percent calories from protein, fat, and carbohydrate as continuous variables), baseline and follow-up age (continuous), and baseline and follow-up BMI [underweight (BMI < 10th percentile), overweight (BMI > 85th percentile), or normal weight]. We decided a priori not to consider height as a covariate due to its strong correlation with IGF-1 during puberty (Silbergeld et al. 1986). We then reduced this model by excluding covariates that did not predict the outcome with p < 0.10, or did not change the estimated association between BLL and IGF-1 by > 10% when removed from the model, resulting in a final model that included baseline parental education, birth weight, nutritional intake, and baseline and follow-up age and BMI.

Because pubertal status is influenced by lead exposure (Selevan et al. 2003; Williams et al. 2010) and may be considered in the causal pathway between BLL and serum IGF-1 concentration, we fit the final reduced model both with and without adjustment for pubertal status (categorized based on tes-ticular volume (TV) as prepubertal, ≤ 3 mL TV; early pubertal, > 3–6 mL TV; or mid-pubertal, > 6–15 mL TV). No boys in this analysis had a TV > 15 mL. We also evaluated whether the association between BLL and IGF-1 concentration differed by pubertal stage by including an interaction term between pubertal status (prepubertal, early pubertal, or mid-pubertal) and BLL (≥ 5 or < 5 μg/dL).

Sensitivity analyses included the following modifications to the final reduced model: a) inclusion of maternal and paternal heights as potential confounding variables for the subset of boys who had these values available (n = 337), b) inclusion of 44 additional boys with only one follow-up IGF-1 concentration. c) BLL, categorized as ≤ 2, 3–4, 5–9, or ≥ 10 μg/dL, and d) BLL modeled as a natural log-transformed continuous variable. We conducted all analyses using SAS version 9.3 (SAS Institute Inc., Cary, NC, USA), and we considered two-sided p-values ≤ 0.05 statistically significant.

### Results

Baseline growth and demographic characteristics of the 394 boys included are shown in Table 1. The 95 eligible boys excluded from the present analysis were not significantly different from those included with regard to the characteristics shown in Table 1, except that they tended to have a higher percent protein intake at baseline and were more likely to have parents that had junior college or technical training (data not shown).

The mean BLL at 8–9 years of age among boys included in the analysis was 3 μg/dL (25th, 75th percentiles: 2 μg/dL, 5 μg/dL; range, 0.5–31 μg/dL). Most boys were prepubertal at baseline. The mean baseline height z-score was slightly above the WHO average, and the mean baseline BMI z-score was slightly below the WHO average (Table 1).

In unadjusted GEE models that accounted only for correlation among study visits, mean serum IGF-1 concentra-tion during follow-up was 24.3 ng/mL lower (95% CI: −39.3, −9.3) among boys with BLL ≥ 5 μg/dL compared with those with < 5 μg/dL. A significantly lower mean IGF-1 concentration for boys with high versus low BLL was also estimated based on the full multivariable model (−28.0 ng/mL; 95% CI: −43.1, −12.9) and the final reduced model (−29.2 ng/mL; 95% CI: −43.8, −14.5).
Table 1. Baseline and follow-up characteristics of 394 boys from Chapaevsk, Russia, with baseline blood lead levels and two longitudinal measures of serum IGF-1.

<table>
<thead>
<tr>
<th>Variable</th>
<th>8–9 years old (baseline)</th>
<th>10–11 years old</th>
<th>12–13 years old</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) (median range)</td>
<td>8.1 (7.8–9.4)</td>
<td>10.1 (9.9–11.5)</td>
<td>12.1 (11.9–13.5)</td>
</tr>
<tr>
<td>BMI (WHO z-score)</td>
<td>Mean ± SD</td>
<td>&lt; 10th percentile (n [%])</td>
<td>&gt; 85th percentile (n [%])</td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>−0.2 ± 1.3</td>
<td>67 (17)</td>
<td>58 (15)</td>
</tr>
<tr>
<td>&lt; 10th percentile</td>
<td>−0.2 ± 1.3</td>
<td>63 (21)</td>
<td>83 (21)</td>
</tr>
<tr>
<td>&gt; 85th percentile</td>
<td>−0.2 ± 1.4</td>
<td>75 (19)</td>
<td>70 (18)</td>
</tr>
<tr>
<td>Height (WHO z-score) (mean ± SD)</td>
<td>0.14 ± 1.0</td>
<td>0.14 ± 1.0</td>
<td>0.03 ± 1.1</td>
</tr>
<tr>
<td>Testicular volume (mL) (mean ± SD)</td>
<td>336 (88)a</td>
<td>213 (54)</td>
<td>52 (13)b</td>
</tr>
<tr>
<td>&lt; 3 (prepubertal)</td>
<td>336 (88)a</td>
<td>213 (54)</td>
<td>52 (13)b</td>
</tr>
<tr>
<td>&gt; 3–6</td>
<td>55 (14)</td>
<td>153 (39)</td>
<td>104 (27)</td>
</tr>
<tr>
<td>&gt; 6</td>
<td>0 (0)</td>
<td>28 (7)</td>
<td>235 (60)</td>
</tr>
<tr>
<td>IGF-1 (ng/mL) (mean ± SD)</td>
<td>244 (62)</td>
<td>39.0 ± 1.74</td>
<td>g/–0.2 ± 1.3</td>
</tr>
<tr>
<td>&lt; 5 [µg/dL]</td>
<td>3.34 ± 0.52</td>
<td>166.9 ± 52.1</td>
<td>253.5 ± 115.9</td>
</tr>
<tr>
<td>Monthly household income (US$) (n [%])</td>
<td>175–250</td>
<td>136 (35)</td>
<td>107 (27)</td>
</tr>
<tr>
<td>≤ 175</td>
<td>175–250</td>
<td>107 (27)</td>
<td>150 (38)</td>
</tr>
<tr>
<td>&gt; 250</td>
<td>25 (6)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>Maximal parental education (n [%])a</td>
<td>25 (6)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>Secondary education or less</td>
<td>122 (31)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>Junior college/technical training</td>
<td>136 (35)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>University graduate</td>
<td>244 (62)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>Blood lead level (µg/dL)</td>
<td>Median (IQR)</td>
<td>3.0 (3.0)</td>
<td>285 (72)</td>
</tr>
<tr>
<td>&lt; 5 [µg/dL]</td>
<td>&lt; 5 [µg/dL]</td>
<td>109 (28)</td>
<td>0.06</td>
</tr>
<tr>
<td>≥ 5 [µg/dL]</td>
<td>285 (72)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breastfeeding duration (weeks) (median IQR)c</td>
<td>13.0 (30.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline nutritional intake (mean ± SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total kcal/day</td>
<td>2,837 ± 972</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent fat</td>
<td>34.1 ± 5.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent protein</td>
<td>11.5 ± 1.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent carbohydrate</td>
<td>54.5 ± 6.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monthly household income (US$) (n [%])</td>
<td>175–250</td>
<td>136 (35)</td>
<td>107 (27)</td>
</tr>
<tr>
<td>≤ 175</td>
<td>175–250</td>
<td>107 (27)</td>
<td>150 (38)</td>
</tr>
<tr>
<td>&gt; 250</td>
<td>25 (6)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>Nutritional intake</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total calories</td>
<td>244 (62)</td>
<td>39.0 ± 1.74</td>
<td>g/–0.2 ± 1.3</td>
</tr>
<tr>
<td>&lt; 5 [µg/dL]</td>
<td>3.34 ± 0.52</td>
<td>166.9 ± 52.1</td>
<td>253.5 ± 115.9</td>
</tr>
<tr>
<td>≥ 5 [µg/dL]</td>
<td>285 (72)</td>
<td>109 (28)</td>
<td></td>
</tr>
<tr>
<td>Fat (percent)</td>
<td>14.0 (2.2–6.5)</td>
<td>2.6 (10.6, 5.5)</td>
<td>0.54</td>
</tr>
<tr>
<td>Protein (percent)</td>
<td>1.4 (0.2–2.9)</td>
<td>1.4 (0.2–2.9)</td>
<td>0.54</td>
</tr>
<tr>
<td>Percent carbohydrate</td>
<td>3.0 (–1.6, 7.6)</td>
<td>3.0 (–1.6, 7.6)</td>
<td>0.54</td>
</tr>
<tr>
<td>Parental education</td>
<td>225 (60)</td>
<td>253.5 ± 115.9</td>
<td>0.03</td>
</tr>
<tr>
<td>Secondary education or less</td>
<td>285 (72)</td>
<td>253.5 ± 115.9</td>
<td></td>
</tr>
<tr>
<td>Junior college/technical training</td>
<td>285 (72)</td>
<td>253.5 ± 115.9</td>
<td></td>
</tr>
<tr>
<td>University graduate</td>
<td>285 (72)</td>
<td>253.5 ± 115.9</td>
<td></td>
</tr>
<tr>
<td>Monthly household income (US$)</td>
<td>Median (IQR)</td>
<td>13.0 (30.3)</td>
<td>253.5 ± 115.9</td>
</tr>
<tr>
<td>&lt; 175</td>
<td>175–250</td>
<td>136 (35)</td>
<td>107 (27)</td>
</tr>
<tr>
<td>&gt; 250</td>
<td>25 (6)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>Pubertal status by testicular volume (mL)</td>
<td>136 (35)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>Prepubertal</td>
<td>136 (35)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>Early pubertal</td>
<td>136 (35)</td>
<td>244 (62)</td>
<td></td>
</tr>
<tr>
<td>Mid-pubertal</td>
<td>136 (35)</td>
<td>244 (62)</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2.** Repeated measures generalized estimating equation models predicting the mean levels of serum concentrations of IGF-1 (ng/mL) in relation to blood lead levels and relevant covariates.

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Full multivariable model</th>
<th>Final reduced model</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 385 boys, 767 visits)</td>
<td>(n = 389 boys, 775 visits)</td>
</tr>
<tr>
<td></td>
<td>Adjusted mean change (95% CI)</td>
<td>p-Value</td>
</tr>
<tr>
<td>Lead (µg/dL)</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>≤ 5</td>
<td>−26.0 (−43.1, −12.9)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>&gt; 5</td>
<td>51.9 (47.2, 56.6)</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Age (years)</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>&lt; 10</td>
<td>−17.4 (−32.2, −1.5)</td>
<td>0.03</td>
</tr>
<tr>
<td>&gt; 10–95</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>&gt; 95</td>
<td>13.8 (−4.4, 31.9)</td>
<td>0.14</td>
</tr>
<tr>
<td>Nutritional intake</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Total calories</td>
<td>−2.6 (−10.7, 5.6)</td>
<td>0.54</td>
</tr>
<tr>
<td>Fat (percent)</td>
<td>1.4 (0.2–2.9)</td>
<td>0.02</td>
</tr>
<tr>
<td>Protein (percent)</td>
<td>3.0 (–1.6, 7.6)</td>
<td>0.21</td>
</tr>
<tr>
<td>Parental education</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Secondary education or less</td>
<td>−22.5 (−45.8, 0.8)</td>
<td>0.06</td>
</tr>
<tr>
<td>Junior college/technical training</td>
<td>−3.4 (−19.3, 12.5)</td>
<td>0.69</td>
</tr>
<tr>
<td>University graduate</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>Monthly household income (US$)</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>&lt; 175</td>
<td>−3.3 (−20.3, 13.8)</td>
<td>0.71</td>
</tr>
<tr>
<td>&gt; 250</td>
<td>−6.4 (−23.7, 10.9)</td>
<td>0.47</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>&lt; 12</td>
<td>0.4 (−4.2, 5.1)</td>
<td>0.85</td>
</tr>
<tr>
<td>≥ 12</td>
<td>0.7 (−18.2, 19.7)</td>
<td>0.94</td>
</tr>
</tbody>
</table>

*Per 1,000 calories.

**Table 2.** Adjusted mean IGF-1 concentrations for high versus low BLL with pubertal status. The adjusted mean IGF-1 difference for high versus low BLL was 14 ng/mL in prepubertal boys, 18 ng/mL in early-pubertal boys, and 42 ng/mL in mid-pubertal boys. Compared with prepubertal boys, the lead-associated IGF-1 difference was larger in mid-pubertal boys (p = 0.04) and larger, but not significantly larger, in early-pubertal boys (p = 0.65).
the reference group: –12.8 ng/mL (95% CI: –29.9, 4.4; n = 176) for BLL = 3–4 μg/dL; –34.5 ng/mL (95% CI: –53.1, –16.0; n = 97) for BLL = 5–9 μg/dL; and –60.4 ng/mL (95% CI: –90.9, –29.9; n = 12) for BLL ≥ 10 μg/dL, compared with BLL ≤ 2 μg/dL (n = 109) (Figure 2). Finally, each unit increase in natural log-transformed BLL was associated with a 22.2-ng/mL decrease in mean serum IGF-1 (95% CI: –33.9, –10.6).

**Discussion**

We observed a negative association between BLLs measured at 8–9 years of age and serum IGF-1 concentrations at 10–11 and 12–13 years of age that was stronger among boys in mid-puberty than in prepubertal boys. This finding suggests one possible explanation for our previous finding of lower mean height z-scores for boys in the same cohort with BLL ≥ 5 μg/dL compared with BLL < 5 μg/dL (Burns et al. 2012). Results from the present analysis suggest a monotonic dose–response relationship between BLL and serum IGF-1 that adds further support to existing evidence of physiological effects of BLLs < 10 μg/dL (Ballew et al. 1999; Bellinger et al. 1992; Gump et al. 2005; Kafourou et al. 1996), and puberty is delayed with occupational lead exposure (mean BLL, 4.1 μg/dL) compared with 26 nonworkers (mean BLL, 33.0 μg/dL) and nine men without occupational exposure (mean BLL, 16 μg/dL) (Klein et al. 1994; Sokol et al. 1998). Furthermore, the net effect of lead on growth in humans cannot be completely understood without information on the association between childhood lead exposures and adult height, so continued longitudinal follow-up through adulthood is warranted for this and other cohorts.

**Conclusion**

In the present study we found a negative monotonic dose–response association between blood lead levels in boys at 8–9 years of age and their serum IGF-1 concentrations at 10–11 and 12–13 years of age. With increasing attention to environmental exposures and potential health risks, it is essential to better understand effects of low-level lead exposure on key developmental processes such as growth and reproductive development.

**References**


**Figure 2.** Adjusted mean IGF-1 concentrations by BLL category. Compared with BLL ≤ 2 μg/dL, the higher BLL levels of 5–9 μg/dL and ≥ 10 μg/dL were associated with significantly lower mean IGF-1 concentrations (p < 0.001 for both comparisons).
and Nutrition Examination Survey (NHANES III), 1988–
Bellinger DC, Stiles KM, Needleman HL. 1992. Low-level lead
exposure, intelligence and academic achievement: a long-
Betta KS. 2012. Serum concentrations of organochlo-
rine pesticides and growth among Russian boys. Environ
Health Perspect 120:303–310.
Camoratto AM, White LM, Lau YS, Ware GO, Berry WD,
Braunstein GD, Dahlgren J, Loriaux DL. 1978. Hypogonadism in
Carlson HE. 1986. Inhibition of prolactin and growth hormone
Divall SA, Williams TR, Carver SE, Koch L, Bruning JC, Kahn CR,
Koch L, Bruning JC, Khan CR. 2001. Effects of lead on
low-level growth and growth hormone release in rats. Toxocol
Carlson HE. 1984. Inhibition of prolactin and growth hormone
Divall SA, Williams TR, Carver SE, Koch L, Bruning JC, Kahn CR,
Koch L, Bruning JC, Khan CR. 2001. Effects of lead on
low-level growth and growth hormone release in rats. Toxocol
Camoratto AM, White LM, Lau YS, Ware GO, Berry WD,
Braunstein GD, Dahlgren J, Loriaux DL. 1978. Hypogonadism in
Carlson HE. 1986. Inhibition of prolactin and growth hormone
Divall SA, Williams TR, Carver SE, Koch L, Bruning JC, Kahn CR,
Koch L, Bruning JC, Khan CR. 2001. Effects of lead on
low-level growth and growth hormone release in rats. Toxocol
Camoratto AM, White LM, Lau YS, Ware GO, Berry WD,
Braunstein GD, Dahlgren J, Loriaux DL. 1978. Hypogonadism in
Carlson HE. 1986. Inhibition of prolactin and growth hormone
Divall SA, Williams TR, Carver SE, Koch L, Bruning JC, Kahn CR,
Koch L, Bruning JC, Khan CR. 2001. Effects of lead on
low-level growth and growth hormone release in rats. Toxocol